Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avidity Biosciences ( (RNA) ) has provided an announcement.
On September 11, 2025, Avidity Biosciences announced an underwriting agreement to issue and sell 15,000,000 shares of its common stock at $40.00 per share, with underwriters purchasing at $37.70 per share. The offering, expected to close on September 15, 2025, could generate approximately $564.0 million, or $648.8 million if an additional option is exercised. The proceeds will support the development of Avidity’s clinical programs, commercial infrastructure, and research and development of its AOC platform.
The most recent analyst rating on (RNA) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
Avidity Biosciences faces significant financial challenges, with ongoing losses and negative cash flow impacting its financial performance score. Technical analysis provides a slightly more positive outlook with some upward momentum, but valuation remains a concern due to negative earnings. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences, Inc. is a biopharmaceutical company focused on developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs). These therapeutics are designed to combine monoclonal antibodies with oligonucleotide therapies to target diseases that current RNA therapies cannot address. The company is advancing clinical programs for rare muscle diseases such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy, as well as precision cardiology development candidates for rare genetic cardiomyopathies. Avidity is based in San Diego, CA.
Average Trading Volume: 2,846,795
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.28B
Learn more about RNA stock on TipRanks’ Stock Analysis page.